Melatonin
Biosynthesis and Regulation
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine synthesized from the essential amino acid L-tryptophan. The pathway proceeds through several enzymatic steps: L-tryptophan is hydroxylated by tryptophan hydroxylase (TPH) to form 5-hydroxytryptophan (5-HTP). 5-HTP is then decarboxylated by aromatic L-amino acid decarboxylase (AADC) to produce serotonin (5-hydroxytryptamine). The subsequent two steps are unique to melatonin synthesis and are primarily localized to the pineal gland. Serotonin is N-acetylated by arylalkylamine N-acetyltransferase (AANAT; EC 2.3.1.87), the rate-limiting enzyme in the pathway, to form N-acetylserotonin. Finally, N-acetylserotonin is O-methylated by acetylserotonin O-methyltransferase (ASMT), also known as hydroxyindole-O-methyltransferase (HIOMT; EC 2.1.1.4), to yield melatonin.
The activity of AANAT is under tight circadian control, driven by environmental light cues. Light information is transmitted from intrinsically photosensitive retinal ganglion cells (ipRGCs) via the retinohypothalamic tract (RHT) to the suprachiasmatic nucleus (SCN). The SCN projects to the paraventricular nucleus (PVN) of the hypothalamus, which in turn sends signals down to the superior cervical ganglion (SCG). Postganglionic sympathetic fibers from the SCG innervate the pineal gland. During darkness, norepinephrine (NE) is released from these fibers, binding to β1- and α1-adrenergic receptors on pinealocytes. This activates a Gs-protein coupled signaling cascade, leading to increased intracellular cyclic AMP (cAMP), which phosphorylates and activates AANAT, dramatically increasing melatonin synthesis and secretion. Conversely, light exposure suppresses NE release, leading to AANAT dephosphorylation and inactivation, thus inhibiting melatonin production.
Receptor Signaling
Melatonin exerts its physiological effects primarily through two high-affinity G-protein coupled receptors (GPCRs): Melatonin Receptor 1 (MT1) and Melatonin Receptor 2 (MT2). Both receptors are coupled to inhibitory G-proteins of the Gαi/o family. They are densely expressed in the SCN, retina, and other central and peripheral tissues.
- MT1 Receptor (MTNR1A): Activation of MT1 receptors leads to the inhibition of adenylyl cyclase, resulting in a decrease in intracellular cAMP levels. This signaling cascade ultimately causes hyperpolarization and inhibition of neuronal firing in the SCN. This 'braking' effect on SCN activity is thought to be the primary mechanism by which melatonin promotes sleep onset and reduces sleep latency.
- MT2 Receptor (MTNR1B): MT2 receptor activation also inhibits adenylyl cyclase but is more specifically linked to the phase-shifting properties of melatonin. It modulates the timing of the circadian clock, helping to entrain it to the 24-hour light-dark cycle. This is crucial for adapting to changes in time zones (jet lag) or work schedules. MT2 signaling can also inhibit cGMP pathways and influence phospholipase C activity.
Pharmacokinetics
Upon oral administration, melatonin is rapidly absorbed, with time to maximum plasma concentration (Tmax) typically occurring within 30 to 60 minutes. However, it undergoes extensive first-pass metabolism in the liver, primarily via hydroxylation by CYP1A2 and CYP2C19 enzymes, followed by conjugation with sulfate or glucuronic acid. This results in low and highly variable oral bioavailability, estimated to be between 3% and 33%. The plasma half-life (t1/2) of exogenous melatonin is short, generally ranging from 30 to 60 minutes. This pharmacokinetic profile explains why standard-release melatonin is effective for initiating sleep but may be less effective for maintaining sleep throughout the night, leading to the development of extended-release formulations.